冠心病患者中的非缺血性或双重心肌病
该注册研究纳入3023例接受冠脉造影提示梗阻性CAD并完成钆对比剂心脏磁共振评估心室功能与瘢痕的患者,中位随访4.8年。结果显示16.9%存在CAD合并NICM或双重心肌病,其全因死亡或心衰住院复合终点风险较CAD合并ICM更高(校正HR 1.23,95%CI 1.06-1.43,P=0.007)。
要点
- 梗阻性CAD患者中约1/6合并NICM或双重心肌病,需考虑CMR鉴别。
- CAD+NICM或双重CM较CAD+ICM的全因死亡或心衰住院风险更高(校正HR 1.23)。
- 合并NICM或双重CM可能解释血运重建对CAD预后获益不足。
核心结论
- 在因临床需要行心脏磁共振的CAD患者中,NICM或双重心肌病见于约1/6患者,且与较ICM更差的长期结局相关。
- 梗阻性CAD患者中偶然合并NICM或双重CM可能 contribute to 血运重建缺乏预后获益。
研究设计与样本
- 多中心注册研究,连续纳入2004至2020年4家医院接受冠脉造影证实梗阻性CAD并完成钆对比剂心脏磁共振评估心室功能与瘢痕的患者。
- 共纳入3023例患者,中位年龄66岁,76%为男性;中位随访4.8年(四分位距2.9-7.6年)。
主要发现
- 18.2%无心肌病,64.8%为缺血性心肌病(CAD+ICM),9.3%为CAD+NICM,7.7%为双重心肌病(CAD+dualCM),合计16.9%存在CAD+NICM或dualCM。
- 随访期间1116例发生主要复合终点(全因死亡或心衰住院)。
- 多变量Cox分析中,CAD+NICM或dualCM较CAD+ICM的主要终点风险更高(校正HR 1.23,95%CI 1.06-1.43,P=0.007)。
- 全因死亡风险更高(HR 1.21,95%CI 1.02-1.43,P=0.032),心衰住院风险更高(HR 1.37,95%CI 1.11-1.69,P=0.003)。
- 心血管死亡风险与CAD+ICM无差异(HR 1.15,95%CI 0.89-1.48,P=0.28)。
临床怎么用
- 对梗阻性CAD患者应关注是否合并NICM或双重心肌病,心脏磁共振可用于鉴别心肌病病因。
- 合并NICM或双重CM的CAD患者长期死亡与心衰住院风险更高,需加强随访与心衰管理。
局限性
- 为注册研究,患者为因临床需要转诊行心脏磁共振者,可能存在选择偏倚。
- 原文未报告针对血运重建与NICM交互作用的随机对照证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Randomized trials in obstructive coronary artery disease (CAD) have largely shown no prognostic benefit from coronary revascularization. Although there are several potential reasons for the lack of benefit, an underexplored possible reason is the presence of coincidental nonischemic cardiomyopathy (NICM). We investigated the prevalence and prognostic significance of NICM in patients with CAD (CAD-NICM). METHODS: We conducted a registry study of consecutive patients with obstructive CAD on coronary angiography who underwent contrast-enhanced cardiovascular magnetic resonance imaging for the assessment of ventricular function and scar at 4 hospitals from 2004 to 2020. We identified the presence and cause of cardiomyopathy using cardiovascular magnetic resonance imaging and coronary angiography data, blinded to clinical outcomes. The primary outcome was a composite of all-cause death or heart failure hospitalization, and secondary outcomes were all-cause death, heart failure hospitalization, and cardiovascular death. RESULTS: Among 3023 patients (median age, 66 years; 76% men), 18.2% had no cardiomyopathy, 64.8% had ischemic cardiomyopathy (CAD+ICM), 9.3% had CAD+NICM, and 7.7% had dual cardiomyopathy (CAD+dualCM), defined as both ICM and NICM. Thus, 16.9% had CAD+NICM or dualCM. During a median follow-up of 4.8 years (interquartile range, 2.9, 7.6), 1116 patients experienced the primary outcome. In Cox multivariable analysis, CAD+NICM or dualCM was independently associated with a higher risk of the primary outcome compared with CAD+ICM (adjusted hazard ratio, 1.23 [95% CI, 1.06-1.43]; P=0.007) after adjustment for potential confounders. The risks of the secondary outcomes of all-cause death and heart failure hospitalization were also higher with CAD+NICM or dualCM (hazard ratio, 1.21 [95% CI, 1.02-1.43]; P=0.032; and hazard ratio, 1.37 [95% CI, 1.11-1.69]; P=0.003, respectively), whereas the risk of cardiovascular death did not differ from that of CAD+ICM (hazard ratio, 1.15 [95% CI, 0.89-1.48]; P=0.28). CONCLUSIONS: In patients with CAD referred for clinical cardiovascular magnetic resonance imaging, NICM or dualCM was identified in 1 of every 6 patients and was associated with worse long-term outcomes compared with ICM. In patients with obstructive CAD, coincidental NICM or dualCM may contribute to the lack of prognostic benefit from coronary revascularization.
引用
- Bawaskar P, Thomas N, Ismail K, et al. Nonischemic or Dual Cardiomyopathy in Patients With Coronary Artery Disease. Circulation. 2023. PMID: 37929565. doi:10.1161/CIRCULATIONAHA.123.067032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。